Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

101. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis

Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

102. A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel

A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

103. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention

Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention Saini SD, Fendrick AM, Scheiman JM Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of proton-pump inhibitor (PPI) co-therapy to reduce dyspepsia in patients aged 50 years or older, receiving long-term, low-dose aspirin, for the secondary prevention of cardiovascular disease

Full Text available with Trip Pro

2011 NHS Economic Evaluation Database.

104. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis

Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

105. A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial (PubMed)

A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial o evaluate the efficacy and tolerability of add-on treatment with lesogaberan (AZD3355), a novel reflux inhibitor, in patients with persistent gastro-oesophageal reflux disease (GORD) symptoms despite proton pump inhibitor (PPI) therapy.double-blind, placebo-controlled, randomised, parallel-group

Full Text available with Trip Pro

2011 EvidenceUpdates

106. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies (PubMed)

Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies Proton pump inhibitors (PPIs) are widely used in several acid-related gastrointestinal disorders. In vivo studies have suggested that gastric suppression by PPIs could result in decreased intestinal calcium absorption. Subsequently, there have been concerns that the chronic use of a PPI is associated with an increased risk of bone fracture. However, the results of clinical studies

2011 EvidenceUpdates

107. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. (PubMed)

Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Concerns have been raised about the risk of fractures with acid-suppressive medications, such as proton pump inhibitors and histamine(2)-receptor antagonists.This meta-analysis evaluated the association between proton pump inhibitor or histamine(2)-receptor antagonist use and fractures. We performed a systematic search of published literature (1970 to October 10, 2010) in MEDLINE, EMBASE, and other (...) sources. Ten publications reporting 11 studies were considered eligible for analysis.All studies were observational case-control or cohort studies and primarily evaluated older adults. The summary effect estimate for risk of hip fracture increased modestly among individuals taking proton pump inhibitors (relative risk [RR] 1.30, 95% confidence interval [CI], 1.19-1.43). There also was an increase in spine (RR 1.56, 95% CI, 1.31-1.85) and any-site fractures (RR 1.16, 95% CI, 1.04-1.30) among proton

Full Text available with Trip Pro

2011 EvidenceUpdates

108. Proton pump inhibitor use and the antifracture efficacy of alendronate (PubMed)

Proton pump inhibitor use and the antifracture efficacy of alendronate Proton pump inhibitors (PPIs) are widely used in elderly patients and are frequently coadministered in users of oral bisphosphonates. Biologically, PPIs could affect the absorption of calcium, vitamin B(12), and bisphosphonates and could affect the osteoclast proton pump, thus interacting with bisphosphonate antifracture efficacy. Moreover, PPIs themselves have been linked to osteoporotic fractures.Population-based, national

Full Text available with Trip Pro

2011 EvidenceUpdates

109. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review (PubMed)

Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review Use of proton-pump inhibitors (PPIs) for the treatment of gastroesophageal reflux disease (GERD) in children has increased enormously. However, effectiveness and safety of PPIs for pediatric GERD are under debate.We performed a systematic review to determine effectiveness and safety of PPIs in children with GERD.We searched PubMed, Embase, and the Cochrane Database of Systematic Reviews

2011 EvidenceUpdates

110. Cost-utility of aspirin and proton pump inhibitors for primary prevention

Cost-utility of aspirin and proton pump inhibitors for primary prevention Cost-utility of aspirin and proton pump inhibitors for primary prevention Cost-utility of aspirin and proton pump inhibitors for primary prevention Earnshaw SR, Scheiman J, Fendrick AM, McDade C, Pignone M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of aspirin with or without a proton-pump inhibitor (PPI) to prevent gastrointestinal bleeding, while preventing coronary heart disease. Adding a PPI to aspirin was not cost-effective for men with an average risk of bleeding, but was potentially cost-effective for men with an increased risk of bleeding. The cost-effectiveness methods were valid and key areas

Full Text available with Trip Pro

2011 NHS Economic Evaluation Database.

111. The Efficacy of Proton Pump Inhibitors for the Treatment of Asthma in Adults: A Meta-analysis. (PubMed)

The Efficacy of Proton Pump Inhibitors for the Treatment of Asthma in Adults: A Meta-analysis. Gastroesophageal reflux disease occurs frequently among patients with asthma. Therapy with proton pump inhibitors (PPIs) to improve asthma control remains controversial. We sought to evaluate the efficacy of PPIs in treatment of asthma using objective and subjective outcome measures.A literature search was undertaken using MEDLINE (1950-January 2010), PubMed (1950-January 2010), EMBASE (1980-January (...) with gastroesophageal reflux disease (mean difference, 16.90 L/min [95% confidence interval, 0.85-32.95]). Analyses of secondary outcomes (asthma symptoms score, Asthma Quality of Life Questionnaire score, evening PEF rate, and forced expiratory volume in 1 second) showed no significant difference between PPIs and placebo.Proton pump inhibitor therapy in adults with asthma results in a small, statistically significant improvement in morning PEF rate. The magnitude of this improvement, however, is unlikely

Full Text available with Trip Pro

2011 EvidenceUpdates

112. The efficacy of proton pump inhibitors for the treatment of asthma in adults: a meta-analysis

The efficacy of proton pump inhibitors for the treatment of asthma in adults: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

113. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention (PubMed)

Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention The aim of the present study was to analyze the effect of drug exposure patterns of clopidogrel and proton pump inhibitors (PPIs) on the clinical outcomes after percutaneous coronary intervention (PCI). Previous analyses predominantly included discharge medications and did not explore the effect of the drug exposure patterns. We analyzed all-cause death, nonfatal myocardial infarction

2011 EvidenceUpdates

114. Cost-Utility of Aspirin and Proton Pump Inhibitors for Primary Prevention (PubMed)

Cost-Utility of Aspirin and Proton Pump Inhibitors for Primary Prevention Aspirin reduces myocardial infarction but increases gastrointestinal tract (GI) bleeding. Proton pump inhibitors (PPIs) may reduce upper GI bleeding. We estimate the cost-utility of aspirin treatment with or without a PPI for coronary heart disease (CHD) prevention among men at different risks for CHD and GI bleeding.We updated a Markov model to compare costs and outcomes of low-dose aspirin plus PPI (omeprazole, 20 mg/d

Full Text available with Trip Pro

2011 EvidenceUpdates

115. Systematic review: Proton pump inhibitors given before endoscopy for upper gastrointestinal bleeding do not improve survival, rebleeding or need for surgery

Systematic review: Proton pump inhibitors given before endoscopy for upper gastrointestinal bleeding do not improve survival, rebleeding or need for surgery Proton pump inhibitors given before endoscopy for upper gastrointestinal bleeding do not improve survival, rebleeding or need for surgery | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about (...) how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Proton pump inhibitors given before endoscopy for upper gastrointestinal bleeding do

2011 Evidence-Based Medicine (Requires free registration)

116. Celecoxib versus non-selective non-steroidal anti-Inflammatory drugs and proton pump inhibitors: clinical effectiveness, safety, and cost-effectiveness

Celecoxib versus non-selective non-steroidal anti-Inflammatory drugs and proton pump inhibitors: clinical effectiveness, safety, and cost-effectiveness Celecoxib versus non-selective non-steroidal anti-Inflammatory drugs and proton pump inhibitors: clinical effectiveness, safety, and cost-effectiveness Celecoxib versus non-selective non-steroidal anti-Inflammatory drugs and proton pump inhibitors: clinical effectiveness, safety, and cost-effectiveness CADTH Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Celecoxib versus non-selective non-steroidal anti-Inflammatory drugs and proton pump inhibitors: clinical effectiveness, safety, and cost-effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2011 Authors' conclusions Limited evidence showed that celecoxib versus non-COX-2 selective non-steroidal

2011 Health Technology Assessment (HTA) Database.

117. Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis

Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

118. Proton pump inhibitors versus histamine-2-receptor antagonists for the management of iatrogenic gastric ulcer after endoscopic mucosal resection or endoscopic submucosal dissection: a meta-analysis of randomized trials

Proton pump inhibitors versus histamine-2-receptor antagonists for the management of iatrogenic gastric ulcer after endoscopic mucosal resection or endoscopic submucosal dissection: a meta-analysis of randomized trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

119. Proton Pump Inhibitors 2.0

Proton Pump Inhibitors 2.0 Proton Pump Inhibitors 2.0 – Clinical Correlations Search Proton Pump Inhibitors 2.0 November 26, 2010 5 min read By Mary C. Whitman, MD Faculty Peer Reviewed and are prescribed to over . Recently, new data has emerged that suggests that we should be more judicious in prescribing PPIs. In a recent development, the FDA announced that it will require new labeling of PPIs indicating that their use at high . This change was prompted, in part, , who took PPIs for at least (...) of proton pump inhibitors. World J Gastroenterol. 2010. 16(19):2323-30. Katz MH. Failing the Acid Test: Benefits of Proton Pump Inhibitors May not justify the risks for many users. Arch Intern Med. 2010;170(9):747-748. Corley DA, Kubo A, Zhao W, Quesenberry C. Proton Pump Inhibitors and Histamine-2 Receptor Antagonists are Associated with Hip Fractures Among At-Risk Patients. Gastrolenterology 2010. March. Epub ahead of print. Reimer C, Sondergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy

2010 Clinical Correlations

120. Clopidogrel (Plavix) and Proton Pump Inhibitors: An Update on the Potential Drug Interaction

Clopidogrel (Plavix) and Proton Pump Inhibitors: An Update on the Potential Drug Interaction Clopidogrel (Plavix®) and Proton Pump Inhibitors: An Update on the Potential Drug Interaction – Clinical Correlations Search Clopidogrel (Plavix®) and Proton Pump Inhibitors: An Update on the Potential Drug Interaction July 28, 2010 5 min read By Antony Q. Pham, Pharm.D. and Reena M. Tejura, Pharm.D. Faculty Peer Reviewed Recent publications have described a potential drug interaction between (...) clopidogrel (Plavix®) and proton pump inhibitors (PPIs). Several retrospective studies have concluded that the use of PPIs can lower the effectiveness of clopidogrel and as a result, increase the possibility of cardiovascular events. Limited data from prospective trials have yet to show a clinical significance from this potential interaction. The Food and Drug Administration (FDA) released an early communication about the ongoing safety review of clopidogrel and omeprazole on January 26, 2009. Over

2010 Clinical Correlations